Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents; a lower-cost ...

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a ...

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva ...

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

Investing.com -- Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) stock rose 2.7% after the company announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection), ...

Saxenda is a brand name for the weight loss injectable medicine, Liraglutide. It was approved by the FDA for weight loss nearly a decade ago. Saxenda has been labeled ‘the skinny jab’ and the ‘miracle ...

Dosage and Administration Saxenda is administered via subcutaneous injection, typically once a day. The dosage may vary depending on individual health factors and the desired weight loss goals.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) said its U.S. affiliate announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection). “With this approval ...